374 related articles for article (PubMed ID: 16374457)
1. Epigenetic inactivation of tumor suppressor genes in serum of patients with cutaneous melanoma.
Marini A; Mirmohammadsadegh A; Nambiar S; Gustrau A; Ruzicka T; Hengge UR
J Invest Dermatol; 2006 Feb; 126(2):422-31. PubMed ID: 16374457
[TBL] [Abstract][Full Text] [Related]
2. Impaired expression and promotor hypermethylation of O6-methylguanine-DNA methyltransferase in retinoblastoma tissues.
Choy KW; Pang CP; To KF; Yu CB; Ng JS; Lam DS
Invest Ophthalmol Vis Sci; 2002 May; 43(5):1344-9. PubMed ID: 11980845
[TBL] [Abstract][Full Text] [Related]
3. Profiling epigenetic inactivation of tumor suppressor genes in tumors and plasma from cutaneous melanoma patients.
Hoon DS; Spugnardi M; Kuo C; Huang SK; Morton DL; Taback B
Oncogene; 2004 May; 23(22):4014-22. PubMed ID: 15064737
[TBL] [Abstract][Full Text] [Related]
4. Gene methylation in gastric cancer.
Qu Y; Dang S; Hou P
Clin Chim Acta; 2013 Sep; 424():53-65. PubMed ID: 23669186
[TBL] [Abstract][Full Text] [Related]
5. Tumor progression through epigenetic gene silencing of O(6)-methylguanine-DNA methyltransferase in human biliary tract cancers.
Koga Y; Kitajima Y; Miyoshi A; Sato K; Kitahara K; Soejima H; Miyazaki K
Ann Surg Oncol; 2005 May; 12(5):354-63. PubMed ID: 15915369
[TBL] [Abstract][Full Text] [Related]
6. Epigenetic inactivation of RAS association domain family protein 1 (RASSF1A) in malignant cutaneous melanoma.
Spugnardi M; Tommasi S; Dammann R; Pfeifer GP; Hoon DS
Cancer Res; 2003 Apr; 63(7):1639-43. PubMed ID: 12670917
[TBL] [Abstract][Full Text] [Related]
7. Frequent epigenetic inactivation of the RASSF1A tumour suppressor gene in testicular tumours and distinct methylation profiles of seminoma and nonseminoma testicular germ cell tumours.
Honorio S; Agathanggelou A; Wernert N; Rothe M; Maher ER; Latif F
Oncogene; 2003 Jan; 22(3):461-6. PubMed ID: 12545168
[TBL] [Abstract][Full Text] [Related]
8. Pattern of expression of genes linked to epigenetic silencing in human breast cancer.
Munot K; Bell SM; Lane S; Horgan K; Hanby AM; Speirs V
Hum Pathol; 2006 Aug; 37(8):989-99. PubMed ID: 16867861
[TBL] [Abstract][Full Text] [Related]
9. Aberrant promoter hypermethylation in serum DNA from patients with silicosis.
Umemura S; Fujimoto N; Hiraki A; Gemba K; Takigawa N; Fujiwara K; Fujii M; Umemura H; Satoh M; Tabata M; Ueoka H; Kiura K; Kishimoto T; Tanimoto M
Carcinogenesis; 2008 Sep; 29(9):1845-9. PubMed ID: 18632757
[TBL] [Abstract][Full Text] [Related]
10. Identification of novel epigenetically modified genes in human melanoma via promoter methylation gene profiling.
Liu S; Ren S; Howell P; Fodstad O; Riker AI
Pigment Cell Melanoma Res; 2008 Oct; 21(5):545-58. PubMed ID: 18627528
[TBL] [Abstract][Full Text] [Related]
11. Promoter hypermethylation profile of ovarian epithelial neoplasms.
Makarla PB; Saboorian MH; Ashfaq R; Toyooka KO; Toyooka S; Minna JD; Gazdar AF; Schorge JO
Clin Cancer Res; 2005 Aug; 11(15):5365-9. PubMed ID: 16061849
[TBL] [Abstract][Full Text] [Related]
12. Promoter methylation status of the MGMT, hMLH1, and CDKN2A/p16 genes in non-neoplastic mucosa of patients with and without colorectal adenomas.
Ye C; Shrubsole MJ; Cai Q; Ness R; Grady WM; Smalley W; Cai H; Washington K; Zheng W
Oncol Rep; 2006 Aug; 16(2):429-35. PubMed ID: 16820927
[TBL] [Abstract][Full Text] [Related]
13. Promoter methylation status of multiple genes in uveal melanoma.
Merhavi E; Cohen Y; Avraham BC; Frenkel S; Chowers I; Pe'er J; Goldenberg-Cohen N
Invest Ophthalmol Vis Sci; 2007 Oct; 48(10):4403-6. PubMed ID: 17898258
[TBL] [Abstract][Full Text] [Related]
14. Association of epigenetic inactivation of RASSF1A with poor outcome in human neuroblastoma.
Yang Q; Zage P; Kagan D; Tian Y; Seshadri R; Salwen HR; Liu S; Chlenski A; Cohn SL
Clin Cancer Res; 2004 Dec; 10(24):8493-500. PubMed ID: 15623630
[TBL] [Abstract][Full Text] [Related]
15. Frequent alterations of Ras signaling pathway genes in sporadic malignant melanomas.
Reifenberger J; Knobbe CB; Sterzinger AA; Blaschke B; Schulte KW; Ruzicka T; Reifenberger G
Int J Cancer; 2004 Apr; 109(3):377-84. PubMed ID: 14961576
[TBL] [Abstract][Full Text] [Related]
16. Tumor suppressor gene promoter hypermethylation in serum of breast cancer patients.
Dulaimi E; Hillinck J; Ibanez de Caceres I; Al-Saleem T; Cairns P
Clin Cancer Res; 2004 Sep; 10(18 Pt 1):6189-93. PubMed ID: 15448006
[TBL] [Abstract][Full Text] [Related]
17. Promoter hypermethylation patterns of p16, O6-methylguanine-DNA-methyltransferase, and death-associated protein kinase in tumors and saliva of head and neck cancer patients.
Rosas SL; Koch W; da Costa Carvalho MG; Wu L; Califano J; Westra W; Jen J; Sidransky D
Cancer Res; 2001 Feb; 61(3):939-42. PubMed ID: 11221887
[TBL] [Abstract][Full Text] [Related]
18. Identification of epigenetic aberrant promoter methylation in serum DNA is useful for early detection of lung cancer.
Fujiwara K; Fujimoto N; Tabata M; Nishii K; Matsuo K; Hotta K; Kozuki T; Aoe M; Kiura K; Ueoka H; Tanimoto M
Clin Cancer Res; 2005 Feb; 11(3):1219-25. PubMed ID: 15709192
[TBL] [Abstract][Full Text] [Related]
19. Epigenetic inactivation of RASSF1a in uveal melanoma.
Maat W; van der Velden PA; Out-Luiting C; Plug M; Dirks-Mulder A; Jager MJ; Gruis NA
Invest Ophthalmol Vis Sci; 2007 Feb; 48(2):486-90. PubMed ID: 17251440
[TBL] [Abstract][Full Text] [Related]
20. Frequent epigenetic silencing of the CpG island promoter of RASSF1A in thyroid carcinoma.
Schagdarsurengin U; Gimm O; Hoang-Vu C; Dralle H; Pfeifer GP; Dammann R
Cancer Res; 2002 Jul; 62(13):3698-701. PubMed ID: 12097277
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
